Nalaganje...
Methotrexate Re-Challenge for Recurrent Primary Central Nervous System Lymphoma
BACKGROUND: The prognosis of primary CNS lymphoma (PCNSL) recurring after methotrexate is poor (objective response rates [ORR] = 26%–53%; 1-year overall survival [OS] = 35%–57%). Salvage PCNSL chemotherapies have been based on the use of different agents to avoid cross-resistance; however, methotrex...
Shranjeno v:
| izdano v: | J Neurooncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5256683/ https://ncbi.nlm.nih.gov/pubmed/24481997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1370-0 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|